Rabbit Polyclonal MAGEA6 Antibody

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04090(MAGEA6 Antibody) at dilution 1/120. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P04090(MAGEA6 Antibody) at dilution 1/120. (Original magnification: ×200)    

  
  

The melanoma-associated antigen A6 (MAGEA6) is a member of the MAGE-A subfamily within the cancer-testis antigen (CTA) family, which is predominantly expressed in germline cells and silenced in most normal somatic tissues. However, MAGEA6 is reactivated in various malignancies, including melanoma, lung, liver, and breast cancers, where its overexpression is linked to tumor progression, metastasis, and poor prognosis. MAGEA6 encodes a protein with a conserved MAGE homology domain (MHD), which facilitates interactions with E3 ubiquitin ligases, modulating ubiquitination pathways involved in cell cycle regulation, apoptosis, and stress responses.

MAGEA6-specific antibodies are critical tools for studying its biological roles and clinical relevance. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect MAGEA6 expression patterns in tumors versus normal tissues. Their specificity helps validate MAGEA6 as a diagnostic or prognostic biomarker and explore its functional mechanisms in oncogenesis. Additionally, MAGEA6 antibodies are essential in developing targeted therapies, including cancer vaccines, adoptive T-cell therapies, or antibody-drug conjugates (ADCs), leveraging its tumor-restricted expression to minimize off-target effects. However, challenges remain due to high homology among MAGE-A family members, necessitating rigorous validation to ensure antibody specificity and avoid cross-reactivity. Research on MAGEA6 continues to advance its potential as both a therapeutic target and a biomarker in precision oncology.